AzTrials
AzTrials

Overweight (BMI > 25)NCT07497555

Anti-Inflammatory Effects of Pecan Nut Oil Supplementation in Adults With Overweight: A Randomized Controlled Parallel-Group Clinical Trial

A study testing Pecan nut oil supplementation in people with Overweight (BMI > 25), run by Universidad Autonoma de Nuevo Leon at 1 site in Mexico.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this clinical trial is to evaluate whether daily supplementation with cold-pressed pecan nut oil can reduce inflammation in adults with overweight. The main questions it aims to answer are: Does pecan nut oil supplementation reduce inflammatory biomarkers, including C-reactive protein (CRP), interleukin-6… Read more about this study

Who is it for?
Ages 18 to 55 yearsHealthy volunteers can take part
Conditions the study is for
Overweight (BMI > 25)
What is being tested?
Pecan nut oil supplementation
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
50 participants
Where
1 siteMexico
Study dates
15 Oct 2025to 30 Jul 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 55 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Adults aged 18 to 65 years
  • Body mass index (BMI) ≥25 and <30 kg/m² (overweight)
  • Willingness to participate and provide written informed consent
  • Ability to comply with study procedures and attend scheduled visits
  • Stable dietary habits and physical activity levels during the study period

Who cannot join

  • Diagnosis of chronic diseases such as diabetes mellitus, cardiovascular disease, liver disease, renal disease, or autoimmune disorders
  • Use of anti-inflammatory medications, lipid-lowering drugs, or dietary supplements within the last 3 months
  • Smoking or excessive alcohol consumption
  • Pregnancy or lactation
  • Known allergy or intolerance to nuts or nut-derived products
  • Participation in another clinical trial within the last 3 months
  • Any condition that, in the investigator's opinion, may interfere with study participation or outcomes

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Mexico1 site, 1 recruiting

  • Facultad de Salud Pública y Nutrición, Universidad Autónoma de Nuevo León

    Monterrey, Nuevo León, 64460

    Heriberto Castro García, PhD, +52 8113404890 ext. 3081, heriberto.castrogr@uanl.edu.mx

    Aurora Stephanie Hilario-Azuara, QFBT, +528146308248, auhilario_al@ciatej.edu.mx

    Recruiting

Other trials in Mexico

About this study

Official title: Anti-Inflammatory Effects of Pecan Nut Oil Supplementation in Adults With Overweight: A Non-Randomized Controlled Parallel-Group Clinical Trial

The goal of this clinical trial is to evaluate whether daily supplementation with cold-pressed pecan nut oil can reduce inflammation in adults with overweight. The main questions it aims to answer are:

Does pecan nut oil supplementation reduce inflammatory biomarkers, including C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α)? Does pecan nut oil supplementation improve biochemical parameters such as fasting blood glucose and lipid profile? Researchers will compare an experimental group receiving pecan nut oil to a control group with no intervention to determine its effect on inflammation and metabolic parameters.

Read more

Participants will:

Consume 30 g/day of cold-pressed pecan nut oil under fasting conditions for 8 weeks (experimental group) Maintain their usual diet and physical activity throughout the study Attend two evaluation visits (baseline and Day 60) for blood sample collection and anthropometric measurements Provide dietary information using a 24-hour dietary recall

Being tested
Pecan nut oil supplementation
Keywords
pecan nut oil, overweight, controlled trial, nutraceuticals, chronic low-grade inflammation
Medical subject headings
Overweight

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Pecan nut oil supplementationDietary supplement

    Pecan nut oil will be administered as a dietary supplement by oral intake in a standardized daily dose of 30 mL/day for 60 days. The oil will be obtained through cold pressing, ensuring minimal processing and preservation of its bioactive compounds, particularly unsaturated fatty acids and antioxidants constituents.

    This intervention is distinguished from conventional dietary interventions by the use of a regionally sourced pecan nut oil with defined physicochemical and oxidative stability characteristics, allowing for controlled evaluation of its nutraceutical potencial. Unlike general dietary modifications, this study focuses on a single, standardized bioactive source to specifically assess its role in modulating inflammatory biomarkers and metabolic parameters in adults with overweight.

Study groups in NCT07497555
Study groupRoleWhat they receive
Pecan nut oil supplementationExperimentalParticipants in the experimental group will receive daily supplementation with pecan nut oil. The oil will be administered orally in standardized dose of 30 mL/day for a period of 60 days. The intervention aims to evaluate the anti-inflammatory effects and impact on metabolic and biochemical parameters in adults with overweight.
Receives: Dietary Supplement: Pecan nut oil supplementation
Control groupNo interventionParticipants in the control group will not receive any supplementation and will be intructed to maintain their usual diet and lifestyle throughout the study period.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in interleukin-6 (IL-6) levels

    The primary outcome will be the change in serum interleukin-6 (IL-6) levels, measured at baseline and after the intervention period, to assess the anti-inflammatory effect of pecan nut oil suplemmentation in adults with overweight.

    Measured: Baseline and after 60 days of intervention

  2. Change in tumor necrosis factor-alpha (TNF-α) levels

    Changes in serum tumor necrosis factor-alpha (TNF-α) levels will be evaluated at baseline and after the intervention period as a key inflammatory marker.

    Measured: Baseline and after 60 days of intervention.

  3. Change in C-reactive protein (CRP) levels

    The primary outcome will be the change in serum C-reactive protein (CRP) levels, measured at baseline and after 60 days of intervention, to evaluate the anti-inflammatory effect of pecan nut oil supplementation in adults with overweight.

    Measured: Baseline and after 60 days after the start of intervention

Secondary outcomes (12)

  1. Body weight (kg)

    Body weight will be measured at baseline and after 60 days of intervention to assess changes associated with pecan nut oil supplementation.

    Measured: Baseline and after 60 days of intervention

  2. Body mass index (BMI)

    Body mass index will be measured at baseline and after 60 days of intervention to assess changes associated with pecan nut oil supplementation.

    Measured: Baseline and after 60 days of intervention

  3. Body fat (%)

    Body fat will be measured at baseline and after 60 days of intervention to assess changes associated with pecan nut oil supplementation.

    Measured: Baseline and after 60 days of intervention

  4. Waist circumference (cm)

    Body weight will be measured at baseline and after 60 days of intervention to assess changes associated with pecan nut oil supplementation.

    Measured: Baseline and after 60 days of intervention

  5. Hip circumference (cm)

    Hip circumference will be measured at baseline and after 60 days of intervention to assess changes associated with pecan nut oil supplementation.

    Measured: Baseline and after 60 days of intervention

  6. Change in fasting blood glucose

    Difference in fasting blood glucose concentration between baseline (Day 0) and end of intervention (Day 60), measured in mg/dL.

    Measured: Baseline and Day 60

  7. Change in triglycerides (TG)

    Difference in serum triglyceride levels between baseline (Day 0) and Day 60, measured in mg/dL.

    Measured: Baseline and Day 60

  8. Change in total cholesterol (TC)

    Difference in total cholesterol levels between baseline (Day 0) and Day 60, measured in mg/dL.

    Measured: Baseline and Day 60

  9. Change in high-density lipoprotein cholesterol (HDL-c)

    Difference in HDL cholesterol levels between baseline (Day 0) and Day 60, measured in mg/dL.

    Measured: Baseline and Day 60

  10. Change in low-density lipoprotein cholesterol (LDL-c)

    Difference in LDL cholesterol levels between baseline (Day 0) and Day 60, measured in mg/dL.

    Measured: Baseline and Day 60

  11. Change in daily energy intake

    Difference in daily energy intake between baseline (Day 0) and Day 60, estimated using 24-hour dietary recall, expressed in kcal/day.

    Measured: Baseline and Day 60

  12. Change in dietary intake assessed by 24-hour recall

    Changes in dietary intake patterns assessed using a 24-hour dietary recall at baseline (Day 0) and Day 60.

    Measured: Baseline and Day 60

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Mar 2026
  2. Study start15 Oct 2025
  3. Primary completion30 Jul 2026 (estimated)
  4. Study completion30 Jul 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07497555
Sponsor's protocol ID
25-FaSPyN-SA-02
Status last verified
Feb 2026
First submitted
23 Mar 2026
Last updated
27 Mar 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Pecan nut oil supplementation in people with Overweight (BMI > 25), run by Universidad Autonoma de Nuevo Leon at 1 site in Mexico.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 27 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Mexico. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in interleukin-6 (IL-6) levels (time frame: Baseline and after 60 days of intervention). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07497555.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Mar 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in